BBIO vs COGT
BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders. COGT: A clinical-stage biotechnology company developing precision protein kinase inhibitors for oncology and genetically defined diseases.
Side-by-side fundamentals
| Metric | BBIO | COGT | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $81.50 | $36.73 | |
| Market cap as of 2026-08-24 | $15.9B | $6.4B | |
| Net margin as of 2026-08-24 | -124.4% | -264.1% | BBIO higher |
| Gross margin as of 2026-08-24 | +95.1% | n/a | |
| Operating margin as of 2026-08-24 | -90.5% | -295.8% | BBIO higher |
| ROE as of 2026-08-24 | -206.7% | -83.3% | COGT higher |
| ROA as of 2026-08-24 | -65.8% | -55.8% | COGT higher |
| Debt / equity as of 2026-08-24 | 8.27 | 0.37 | COGT lower |
| Revenue growth (YoY) as of 2026-08-24 | +355.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +86.3% | n/a | |
| Beta as of 2026-08-24 | 0.95 | 0.31 | |
| 1-year return as of 2026-08-21 close | +62.3% | +212.1% | COGT higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.